The Latest Breaking News from Biogen

Eli Lilly stock popped Wednesday after the company said its experimental Alzheimer's treatment significantly slowed cognitive decline.

U.S. health regulators have approved a first-of-a-kind drug for a rare form of Lou Gehrig’s disease

The FDA approved Biogen's new ALS drug on Tuesday, but Biogen stock remained hamstrung on a "low-quality earnings beat."

Biogen stock jumped — as Ionis stock gave back early gains — after a FDA panel offered a mixed view of their ALS treatment.

The U.S. Veterans Health Administration will pay for some beneficiaries to get a new Alzheimer’s disease drug from Eisai Co. and Biogen Inc., positive news for a treatment that Eisai expects to bring in billions of dollar in sales in the next few years.

Eli Lilly stock and Biogen stock diverged Thursday after Lilly said a decade-long study of an Alzheimer's treatment definitively failed.

Biogen stock was hamstrung Wednesday on mixed 2023 guidance that assumes expenses for its new Alzheimer's drug will outpace sales.

The Dow Jones fell 200 points Wednesday on strong U.S. retail sales data. Tesla stock reversed lower even after a Barclays outperform rating.

The market rally held up despite hot inflation data. Boeing led new buys while Tesla ran higher. Airbnb soared late on earnings.

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

A treatment that improves Alzheimer’s disease would be a great advance, but Leqembi (lecanemab), which recently received accelerated approval from the FDA, is not that drug. Yes, lecanemab slows decline to an extent detectable on a test, but not to an extent that a relative or caretaker would notice. This…